As of close of business last night, Humana Inc.’s stock clocked out at $347.39, down -0.23% from its previous closing price of $348.19. In other words, the price has decreased by -$0.80 from its previous closing price. On the day, 1402706 shares were traded.
Ratios:
To gain a deeper understanding of HUM’s stock, we examine its different ratios. In the meantime, Its Debt-to-Equity ratio is 0.75 whereas as Long-Term Debt/Eq ratio is at 0.66.
On March 06, 2024, Barclays started tracking the stock assigning a Equal Weight rating and target price of $356.
Cantor Fitzgerald Downgraded its Overweight to Neutral on January 26, 2024, while the target price for the stock was maintained at $391.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 20 ’24 when Mesquita Jorge S. bought 545 shares for $367.09 per share. The transaction valued at 200,066 led to the insider holds 2,578 shares of the business.
Diamond Susan M sold 4,156 shares of HUM for $2,187,226 on May 04 ’23. The Chief Financial Officer now owns 3,931 shares after completing the transaction at $526.28 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HUM now has a Market Capitalization of 41.88B and an Enterprise Value of 49.19B. As of this moment, Humana’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.52, and their Forward P/E ratio for the next fiscal year is 14.29. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.37. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.39 while its Price-to-Book (P/B) ratio in mrq is 2.61. Its current Enterprise Value per Revenue stands at 0.46.
Stock Price History:
Over the past 52 weeks, HUM has reached a high of $541.21, while it has fallen to a 52-week low of $334.54. The 50-Day Moving Average of the stock is 372.00, while the 200-Day Moving Average is calculated to be 452.49.
Shares Statistics:
It appears that HUM traded 1.99M shares on average per day over the past three months and 1.35M shares per day over the past ten days. A total of 122.22M shares are outstanding, with a floating share count of 120.12M. Insiders hold about 0.35% of the company’s shares, while institutions hold 94.64% stake in the company. Shares short for HUM as of Feb 29, 2024 were 2.24M with a Short Ratio of 1.13, compared to 2.26M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.86% and a Short% of Float of 1.86%.
Dividends & Splits
With its trailing 12-month dividend rate of 3.54, HUM has a forward annual dividend rate of 3.54. Against a Trailing Annual Dividend Yield of 1.02%, it implies a Forward Annual Dividend Yield of 1.02%. The stock’s 5-year Average Dividend Yield is 0.67. The current Payout Ratio is 17.70% for HUM, which recently paid a dividend on Apr 26, 2024 with an ex-dividend date of Mar 27, 2024. Stock splits for the company last occurred on Aug 01, 1991 when the company split stock in a 3:2 ratio.
Earnings Estimates
As of right now, 18 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $6.16 for the current quarter, with a high estimate of $8.11 and a low estimate of $5.82, while EPS last year was $9.38. The consensus estimate for the next quarter is $5.9, with high estimates of $8.12 and low estimates of $4.31.
Analysts are recommending an EPS of between $18.84 and $16 for the fiscal current year, implying an average EPS of $16.36. EPS for the following year is $24.61, with 19 analysts recommending between $28.23 and $23.
Revenue Estimates
In the current quarter, 15 analysts expect revenue to total $28.35B. It ranges from a high estimate of $29.6B to a low estimate of $27.44B. As of the current estimate, Humana Inc.’s year-ago sales were $25.65B, an estimated increase of 10.50% from the year-ago figure. For the next quarter, 15 analysts are estimating revenue of $27.98B, an increase of 8.70% less than the figure of $10.50% in the same quarter last year. There is a high estimate of $28.61B for the next quarter, whereas the lowest estimate is $27.35B.
A total of 15 analysts have provided revenue estimates for HUM’s current fiscal year. The highest revenue estimate was $113.64B, while the lowest revenue estimate was $108.91B, resulting in an average revenue estimate of $111.47B. In the same quarter a year ago, actual revenue was $102.64B, up 8.60% from the average estimate. Based on 14 analysts’ estimates, the company’s revenue will be $116.31B in the next fiscal year. The high estimate is $123.94B and the low estimate is $109.52B. The average revenue growth estimate for next year is up 4.30% from the average revenue estimate for this year.
